719 final Flashcards

1
Q

Diabetic peripheral neuropathy is caused by

A

inflammation or damage in the periphery combined with central disturbance in pain processing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Meperidine

A

a potent serotonin reuptake inhibitor and should not be given with MAOIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mechanism & cause for “wide spread pain”:

A

“Suprasegmental” central sensitization is hypothesized to be linked to plastic changes that occur in brain sites within the nociceptive pathway, especially the thalamus and cortex, in the presence of known peripheral causes or even in the absence of identifiable triggering events (ex. wide spread pain). In the case of peripherally activated suprasegmental central sensitization, it it as though the brain “learns” from its experience of pain, and decides not only to keep the process going, but also to enhance it and make it permanent. In the case of pain that originates centrally without peripheral input, it is as though the brain has figured out how to spontaneously activate its pain pathways. Conditions hypothesized to be caused by suprasegmental central sensitization syndromes of pain originating tin the brain without peripheral pain input include fibromyalgia, the syndrome of chronic widespread pain, and painful physical Sx of depression and anxiety Dos, especially PTSD.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Mechanism & cause for diabetic peripheral neuropathy:

A

Neuropathic pain arises from damage to, or dysfunction of, any part of the peripheral or central nervous system, whereas “normal” pain is caused by activation of nociceptive nerve fibers. Peripheral mechanisms in neuropathic pain Normal transduction and conduction in peripheral afferent neurons can be hijacked in certain neuropathic pain states to maintain nociceptive signaling in the absence of a relevant noxious stimulus. Neuronal damage by disease or trauma can alter electrical activity of neurons, allow cross-talk btw neurons, and initiate inflammatory processes to cause peripheral sensitization.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

SSRIs may have

A

inconsistent effects on pain because serotonin can both inhibit and facilitate ascending nociceptive signals.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Milnacipran

A

can alleviate physical pain (fibromyalgia) and has potential effect on cognitive functioning.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Duloxetine

A

can treat both chronic pain and depression without significant side effects.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Zolpidem

A

Ambien. Non-benzo hypnotic.

Short-term Tx of insomnia (controlled-release indication is not restricted to short-term)

As needed for the Tx of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep and there are at least 4 hours of bedtime remaining before the planned time of wakening (Intermezzo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Zolpidem dose

A

10 mg/day at bedtime for 7–10 days (immediate), 12.5 mg/day (controlled)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Zaleplon

A

Sonata. Non-benzo hypnotic.

Short-term Tx of insomnia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Zaleplon dose

A

10 mg/day at bedtime for 7–10 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Flurazepam

A

Dalmane. Benzo (hypnotic).

Insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening

Recurring insomnia or poor sleeping habits /Acute or chronic medical situations requiring restful sleep

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Temazepam

A

Restoril. Benzo (hypnotic).

Short-term treatment of insomnia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

All of these medications are schedule

A

IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Sertraline and zolpidem

A

Sertraline increases plasma levels of zolpidem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

A 72-year-old woman has difficulty falling asleep and frequent nighttime awakenings. The best medicine for her is

A

zolpidem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Eszopiclone

A

Lunesta.

approved for insomnia without S/E of tolerance/dependence.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

the mechanism to treat insomnia with the least amount of psychomotor impairment.

A

Melatonin receptor stimulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

DSM-5 Dx for ADHD

A

(Sx in two or more settings)
· Inattention: ­6 Sx have persisted for at least 6 months (­5 Sx for over age 17)
· 1. Often fails to give close attention to details or makes careless mistakes 2. Often has difficulty sustaining attention in tasks or play activities 3. Often does not seem to listen when spoken to directly 4. Often has difficulty organizing tasks and activities 6. Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort 7. Often loses things necessary for tasks or activities 8. Is often distracted by extraneous stimuli 9. Is often forgetful in daily activities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Hyperactivity and impulsivity Dx

A

6 Sx for at least 6 months (­5 Sx for over age 17)
· 1. Often fidgets with or taps hands or feet or squirms in seat 2. Often leaves seat in situations when remaining seated is expected 3. Often runs about or climbs in situations where it is inappropriate 4. Often unable to play or engage in leisure activities quietly 5. Is often “on the go,” acting as if “driven by a motor” 6. Often talks excessively 7. Often blurts out an answer before a question has been completed 8. Often has difficulty waiting his or her turn 9. Often interrupts or intrudes on others
· The age threshold for diagnosing ADHD changed from 7 to 12 years old.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Sustained attention is hypothetically modulated by the

A

cortico-striatal-thalamic-cortical loop involving the dorsolateral prefrontal cortex (DLPFC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Amphetamine (Dexedrine)

A

stimulant (Schedule II)

ADHD (­6 or ­3 depending on formula), Narcolepsy (­12 or ­6)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Amphetamine (Adderall)

A

stimulant (Schedule II)

ADHD ages 3–12 (Adderall, Evekeo),
ADHD ages 6–17 (Adderall XR, Evekeo, Dyanavel XR, Adzenys XR-ODT)
and in adults (Adderall XR, Evekeo, Adzenys XR-ODT), Narcolepsy (Adderall, Evekeo),
Exogenous obesity (Evekeo)

24
Q

Lisdexamfetamine

A

Vyvanse stimulant (Schedule II)

ADHD age ­6, Binge eating disorder

25
Q

Atomoxetine

A

(Strattera) Selective Norepinephrine Reuptake Inhibitor (NRI)

ADHD in adults and children ­6

26
Q

Guanfacine (Intuniv)

A

Hypertension, ADHD in children ages 6–17 (Intuniv, adjunct and monotherapy)

27
Q

5 A’s

A

ask, Advise, Assess, Assist, and Arrange follow up

28
Q

Ask about tobacco use

A

Identify & document tobacco use status of every pt at every visit.

29
Q

Advise to quit

A

In a clear, strong & personalized manner urge every tobacco user to quit.

30
Q

Assess

A

For current tobacco user, is the tobacco user willing to make a quit attempt at this time? For the ex-tobacco user, how recent did you quit and are there any challenges to remaining abstinent?

31
Q

Assist

A

For the pt willing to make a quit attempt, offer med & provide or refer for counseling or additional behavioral Tx to help the pt quit. For pts unwilling to quit at this time, provide motivational interventions designed to increase future quit attempts. For the recent quitter & any with remaining challenges, provide relapse prevention.

32
Q

Arrange

A

All those receiving the previous A’s should receive follow up

33
Q

tobacco dependence is a chronic disease that often requires repeated intervention and multiple attempts to quit. Effective Tx

A

exist, however, that can significantly increase rates of long-term abstinence.

34
Q

tobacco dependence Tx are effective for

A

a broad range of populations.

35
Q

Brief tobacco dependence Tx is

A

effective. Clinicians should offer every pt who uses tobacco at least the brief Tx shown to be effective in the Guideline.

36
Q

individual, group, and telephone counseling are

A

effective and their effectiveness increases with Tx intensity

37
Q

2 components of counseling are especially effective:

A

Practical counseling (problem-solving/skills training), Social support

38
Q

Numerous effective meds for tobacco dependence and clinicians should encourage their use by all pts attempting to quit smoking, except when

A

medically contraindicated or with specific populations for which there is insufficient evidence of effectiveness (i.e., pregnant women, smokeless tobacco users, light smokers, adolescents)

39
Q

Recommended front-line meds: Seven 1st line meds

A

(5 nicotine & 2 non) reliably increase long-term smoking abstinence rates (Bupropion SR, Nicotine gum/inhaler/lozenge/nasal spray/patch, Varenicline)

40
Q

Counseling and med are effective when used by themselves for treating tobacco dependence. However,

A

the combination of counseling and med is more effective than either alone

41
Q

Telephone quit line counseling is

A

effective with diverse populations and has broad reach

42
Q

If a tobacco user is currently unwilling to make a quit attempt, clinicians should

A

use the motivational Tx shown in the Guideline to be effective in increasing future quit attempts.

43
Q

Tobacco dependence Tx are both clinically effective and highly

A

cost-effective

44
Q

XR-Naltrexone by IM and advantages to choosing Naltrexone IM:

A

Adherence

45
Q

Naltrexone

A

(Revia: oral, Vivitrol: injection)

FDA: Alcohol dependence, Blockade of effects of exogenously administered opioids (oral), Prevention of relapse to opioid dependence (injection)

46
Q

Naltrexone contraindication

A

taking opioid analgesics /currently dependent on opioids or is in acute opiate withdrawal /failed the naloxone challenge test or a positive urine screen for opioids

/acute hepatitis or liver failure /proven allergy to naltrexone /proven allergy to polylactideco-glycolide (PLG), arboxymethylcellulose, or any other components of the diluent (injection)

47
Q

Acamprosate

A

Campral

Maintenance of alcohol abstinence

48
Q

Disulfiram

A

Antabuse

FDA: Maintenance of alcohol abstinence

49
Q

3 drugs approved by the FDA to treat opioid dependence:

A

buprenorphine, methadone, and naltrexone

50
Q

maximum recommended duration of buprenorphine, methadone, and naltrexone

A

no maximum

51
Q

FDA-approved buprenorphine products for the Tx of opioid dependence include:

A

Bunavail (buprenorphine and naloxone) buccal film

/Cassipa (buprenorphine and naloxone) sublingual film

/Probuphine (buprenorphine) implant for subdermal administration /
Sublocade

Suboxone

Subutex (buprenorphine)

Zubsolv (buprenorphine and naloxone) sublingual tablets

52
Q

· FDA-approved methadone products for the Tx of opioid dependence include:

A

Dolophine (methadone hydrochloride) tablets

Methadose (methadone hydrochloride) oral concentrate

53
Q

FDA-approved naltrexone products for the Tx of opioid dependence include:

A

Vivitrol

54
Q

opioid withdrawal syndrome is characterized by

A

the patient feeling dysphoria, craving another dose of opioid, being irritable, and having signs of autonomic hyperactivity such as tachycardia, tremor, and sweating. Pilo-erection (“goose-bumps”) is often associated with opioid withdrawal, especially when drug is stopped suddenly (“cold turkey”).

55
Q

Opioid receptors can readapt to normal if

A

given a chance to do so in the absence of additional intake of an opioid (you don’t take opioids for a long time).